RT Journal Article SR Electronic T1 Characterisation of the mechanism by which a nonsense variant in RYR2 results in ventricular arrhythmia JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2021.03.16.21252576 DO 10.1101/2021.03.16.21252576 A1 Hopton, Claire A1 Tijsen, Anke J A1 Maizels, Leonid A1 Arbel, Gil A1 Gepstein, Amira A1 Bates, Nicola A1 Brown, Benjamin A1 Huber, Irit A1 Kimber, Susan J A1 Newman, William G A1 Venetucci, Luigi A1 Gepstein, Lior YR 2021 UL http://medrxiv.org/content/early/2021/03/24/2021.03.16.21252576.abstract AB Background Heterozygous variants in the cardiac ryanodine receptor gene (RYR2) cause catecholaminergic polymorphic ventricular tachycardia (CPVT). Most pathogenic RYR2 variants are missense variants which result in a gain of function, causing ryanodine receptors to be increasingly sensitive to activation by calcium, have an increased open probability and an increased propensity to develop calcium waves. However, some RYR2 variants can lead to arrhythmias by a loss of function mechanism.Objective To understand the mechanism by which a novel nonsense variant in RYR2 p.(Arg4790Ter) leads to ventricular arrhythmias.Methods Human induced pluripotent stem cells (hiPSCs) harbouring the novel nonsense variant in RYR2 were differentiated into cardiomyocytes (RYR2-hiPSC-CMs) and molecular and calcium handling properties were studied.Results RYR2-hiPSC-CMs displayed significant calcium handling abnormalities at baseline and following treatment with isoproterenol. Treatment with carvedilol and nebivolol resulted in a significant reduction in calcium handling abnormalities in the RYR2-hiPSC-CMs. Expression of the mutant RYR2 allele was confirmed at the mRNA level and partial silencing of the mutant allele resulted in a reduction in calcium handling abnormalities at baseline.Conclusion The nonsense variant behaves similarly to other gain of function variants in RYR2. Carvedilol and nebivolol may be suitable treatments for patients with gain of function RYR2 variants.Competing Interest StatementThe authors have declared no competing interest.Funding StatementCH was supported by the British Heart Foundation (FS/16/33/32196) and the BIRAX Regenerative Medicine Initiative. WGN is supported by the Manchester NIHR BRC (IS-BRC-1215-20007). AJT was supported by NWO (Rubicon 825.13.007) and ZonMw (VENI 91616150).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Central Manchester Research Ethics CommitteeAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesOriginal source data and further clinical details can be provided upon request.